{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T02:52:14Z","timestamp":1776221534191,"version":"3.50.1"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,7,1]],"date-time":"2007-07-01T00:00:00Z","timestamp":1183248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Cancer"],"published-print":{"date-parts":[[2007,7]]},"DOI":"10.1038\/nrc2168","type":"journal-article","created":{"date-parts":[[2007,6,22]],"date-time":"2007-06-22T09:50:27Z","timestamp":1182505827000},"page":"554-562","source":"Crossref","is-referenced-by-count":311,"title":["Targeting the protein kinase C family: are we there yet?"],"prefix":"10.1038","volume":"7","author":[{"given":"Helen J.","family":"Mackay","sequence":"first","affiliation":[]},{"given":"Christopher J.","family":"Twelves","sequence":"additional","affiliation":[]}],"member":"297","reference":[{"key":"BFnrc2168_CR1","first-page":"519","volume-title":"Methods in Molecular Biology","author":"AP Fields","year":"2003","unstructured":"Fields, A. P. & Gustafson, W. C. in Methods in Molecular Biology (ed. Newton, A. C.) 519\u2013537 (Humana Press Inc., Totowa, New Jersey, 2003)."},{"key":"BFnrc2168_CR2","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1007\/BF00666107","volume":"13","author":"GC Blobe","year":"1994","unstructured":"Blobe, G. C., Obeid, L. M. & Hannun, Y. A. Regulation of protein kinase C and role in cancer biology. Cancer Met. Rev. 13, 724\u2013730 (1994).","journal-title":"Cancer Met. Rev."},{"key":"BFnrc2168_CR3","doi-asserted-by":"crossref","first-page":"7847","DOI":"10.1016\/S0021-9258(18)34459-4","volume":"257","author":"M Castagna","year":"1982","unstructured":"Castagna, M. et al. Direct activation of calcium-activated, phopholipid-dependent protein kinase by tumour-promoting phorbol esters. J. Biol. Chem. 257, 7847\u20137851 (1982).","journal-title":"J. Biol. Chem."},{"key":"BFnrc2168_CR4","first-page":"386","volume":"10","author":"H Mackay","year":"2003","unstructured":"Mackay, H. & Twelves, C. J. Protein kinase C: a target for anticancer drugs? Endocrine Relat. Cancer 10, 386\u2013396 (2003).","journal-title":"Endocrine Relat. Cancer"},{"key":"BFnrc2168_CR5","doi-asserted-by":"crossref","unstructured":"Takai, Y. et al. Calcium-dependent activation of a multi-functional protein kinase by membrane phospholipids. J. Biol. Chem. 3692\u20133695 (1979).","DOI":"10.1016\/S0021-9258(18)50638-4"},{"key":"BFnrc2168_CR6","doi-asserted-by":"publisher","first-page":"28495","DOI":"10.1074\/jbc.270.48.28495","volume":"270","author":"AC Newton","year":"1995","unstructured":"Newton, A. C. Protein kinase C; structure, function, and regulation. J. Biol. Chem. 270, 28495\u201328498 (1995).","journal-title":"J. Biol. Chem."},{"key":"BFnrc2168_CR7","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1126\/science.1411571","volume":"258","author":"Y Nishizuka","year":"1992","unstructured":"Nishizuka, Y. Intracellular signalling by hydrolysis of phospholipids and activation of protein kinase C. Science 258, 607\u2013614 (1992).","journal-title":"Science"},{"key":"BFnrc2168_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0167-4889(98)00178-5","volume":"1449","author":"PW Schenk","year":"1999","unstructured":"Schenk, P. W. & Snaar-Jagalska, B. E. Signal perception and transduction: the role of protein kinases. Biochem. Biophys. Acta 1449, 1\u201324 (1999).","journal-title":"Biochem. Biophys. Acta"},{"key":"BFnrc2168_CR9","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1006\/excr.1994.1041","volume":"210","author":"MH Disatnik","year":"1994","unstructured":"Disatnik, M. H., Buraggi, G. & Mochly-Rosen, D. Localisation of protein kinase C isozymes in cardiac myocytes. Exp. Cell Res. 210, 287\u2013297 (1994).","journal-title":"Exp. Cell Res."},{"key":"BFnrc2168_CR10","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1006\/phrs.1998.0418","volume":"39","author":"M Csuki","year":"1999","unstructured":"Csuki, M. and Mochley-Rosen, D. Pharmacologic modulation of protein kinase C isozymes: the role of RACKs and subcellular localisation. Pharmacol. Res. 39, 253\u2013259 (1999).","journal-title":"Pharmacol. Res."},{"key":"BFnrc2168_CR11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0165-6147(00)01468-1","volume":"21","author":"KJ Way","year":"2000","unstructured":"Way, K. J., Chou, E. & King, G. L. Identification of PKC-isoform-specific biological actions using pharmacological approaches. Trends Parmacol. Sci. 21, 181\u2013187 (2000).","journal-title":"Trends Parmacol. Sci."},{"key":"BFnrc2168_CR12","first-page":"75","volume-title":"Protein kinase C","author":"S Ohno","year":"1997","unstructured":"Ohno, S. in Protein kinase C (eds Parker, P. J. & Deckker, L. V.) 75\u201395 (RG Landes, USA, 1997)."},{"key":"BFnrc2168_CR13","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1128\/MCB.17.2.732","volume":"17","author":"H Cai","year":"1997","unstructured":"Cai, H. et al. Role of diacylglycerol-regulated protein kinase C isotypes in growth factor activation of the Raf-1 protein kinase. Mol. Cell. Biol. 17, 732\u2013741 (1997).","journal-title":"Mol. Cell. Biol."},{"key":"BFnrc2168_CR14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/383127a0","volume":"383","author":"CJ Marshall","year":"1996","unstructured":"Marshall, C. J. Cell signalling; Raf gets it together. Nature 383, 127\u2013128 (1996).","journal-title":"Nature"},{"key":"BFnrc2168_CR15","doi-asserted-by":"publisher","first-page":"23512","DOI":"10.1074\/jbc.271.38.23512","volume":"271","author":"Y Ueda","year":"1996","unstructured":"Ueda, Y. et al. Protein kinase C \u03b4 activates the MERK-ERK pathway in a manner independent of Ras and dependent on Raf. J. Biol. Chem. 271, 23512\u201323519 (1996).","journal-title":"J. Biol. Chem."},{"key":"BFnrc2168_CR16","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0014-5793(00)02162-1","volume":"484","author":"A Balendran","year":"2000","unstructured":"Balendran, A. et al. Further evidence that 3-phosphoinositidedependent protein kinase-1 (PDK1) is required for thestability and phosphorylation of protein kinase C (PKC) isoforms. FEBS Lett. 484, 217\u2013223 (2000).","journal-title":"FEBS Lett."},{"key":"BFnrc2168_CR17","first-page":"2462","volume":"45","author":"CA O'Brian","year":"1985","unstructured":"O'Brian, C. A., Liskamp, R. M., Solomon, D. H. & Weinstein, I. B. Inhibition of protein kinase C by tamoxifen. Cancer Res. 45, 2462\u20132465 (1985).","journal-title":"Cancer Res."},{"key":"BFnrc2168_CR18","first-page":"375","volume":"46","author":"K Takenaga","year":"1996","unstructured":"Takenaga, K. & Takahashi, K. Effects of 12-O-tetradecanoylphorbol-13-acetate on adhesiveness and lung-colonising ability of Lewis lung carcinoma cells. Cancer Res. 46, 375\u2013380 (1996).","journal-title":"Cancer Res."},{"key":"BFnrc2168_CR19","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1093\/jnci\/85.5.402","volume":"85","author":"GK Schwartz","year":"1993","unstructured":"Schwartz, G. K., Juang, K., Kelsen, D. & Albino, A. P. Protein kinase C: a novel target for inhibiting gastric cancer cell invasion. J. Natl Cancer Inst. 85, 402\u2013407 (1993).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrc2168_CR20","doi-asserted-by":"crossref","first-page":"15847","DOI":"10.1016\/S0021-9258(18)82331-6","volume":"268","author":"NR Murray","year":"1993","unstructured":"Murray, N. R. et al. Protein kinase C isotypes in human erythroleukaemia (K562) cell proliferation and differentiation. Evidence that \u03b2II protein kinase C is required for proliferation. J. Biol Chem. 268, 15847\u201315853 (1993).","journal-title":"J. Biol Chem."},{"key":"BFnrc2168_CR21","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1083\/jcb.145.4.699","volume":"145","author":"NR Murray","year":"1999","unstructured":"Murray, N. R. et al. Overexpression of protein kinase C \u03b2II induces colonic hyperproliferation and increased sensitivity to colon carcinogenesis. J. Cell Biol. 145, 699\u2013711 (1999).","journal-title":"J. Cell Biol."},{"key":"BFnrc2168_CR22","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1053\/gast.2001.25287","volume":"120","author":"JD Black","year":"2001","unstructured":"Black, J. D. Protein kinase C isozymes in colon carcinogenesis: guilt by omission. Gastroenterology 120, 1868\u20131872 (2001).","journal-title":"Gastroenterology"},{"key":"BFnrc2168_CR23","first-page":"1375","volume":"61","author":"Y Gokmen-Polar","year":"2001","unstructured":"Gokmen-Polar, Y. et al. Elevated protein kinase C \u03b2II is an early promotive event in colon carcinogenesis. Cancer Res. 61, 1375\u20131381 (2001).","journal-title":"Cancer Res."},{"key":"BFnrc2168_CR24","first-page":"523","volume":"44","author":"K Suga","year":"1998","unstructured":"Suga, K. et al. Down-regulation of protein kinase C \u03b1 detected in human colorectal cancer. Biochem. Mol. Biol. Int. 44, 523\u2013528 (1998).","journal-title":"Biochem. Mol. Biol. Int."},{"key":"BFnrc2168_CR25","first-page":"3215","volume":"49","author":"CA O' Brian","year":"1989","unstructured":"O' Brian, C. A., Vogel, V. G., Singletary, S. E. & Ward, N. E. Elevated protein kinase C expression in human breast tumour biopsies relative to normal breast tissue. Cancer Res. 49, 3215\u20133217 (1989).","journal-title":"Cancer Res."},{"key":"BFnrc2168_CR26","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/ijc.2910400310","volume":"40","author":"C Borner","year":"1987","unstructured":"Borner, C. et al. Immunological quantitation of phospholipid\/Ca+- dependent protein kinase of human mammary carcinoma cells: inverse relationship to estrogen receptors. Int. J. Cancer 40, 344\u2013348 (1987).","journal-title":"Int. J. Cancer"},{"key":"BFnrc2168_CR27","first-page":"1187","volume":"7","author":"A Manni","year":"1996","unstructured":"Manni, A. et al. Induction of a less aggressive breast cancer phenotype by protein kinase C-\u03b1 and \u03b2-overexpression. Cell Growth Differ. 7, 1187\u20131198 (1996).","journal-title":"Cell Growth Differ."},{"key":"BFnrc2168_CR28","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1172\/JCI119006","volume":"98","author":"P Xia","year":"1996","unstructured":"Xia, P. et al. Characterisation of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J. Clin. Invest. 98, 2018\u20132026 (1996).","journal-title":"J. Clin. Invest."},{"key":"BFnrc2168_CR29","first-page":"70","volume":"47","author":"EE Cohen","year":"2006","unstructured":"Cohen, E. E. et al. Protein kinase C \u03b6 mediates EGF-induced growth of head and neck tumor cells regulating MAP kinase. Proc. Amer. Assoc. Cancer Res. 47, abs. 70 (2006).","journal-title":"Proc. Amer. Assoc. Cancer Res."},{"key":"BFnrc2168_CR30","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/0006-2952(93)90123-E","volume":"45","author":"JM Herbert","year":"1993","unstructured":"Herbert, J. M. Protein kinase C: a key factor in the regulation of tumor cell adhesion to the endothelium. Biochem. Pharmacol. 45, 527\u2013537 (1993).","journal-title":"Biochem. Pharmacol."},{"key":"BFnrc2168_CR31","first-page":"1349","volume":"12","author":"M Morse-Gaudio","year":"1998","unstructured":"Morse-Gaudio, M., Connolly, J. M. & Rose, D. P. Protein kinase C and its isoforms in human breast cancer cells: relationship to the invasive phenotype. Int. J. Oncol. 12, 1349\u20131354 (1998).","journal-title":"Int. J. Oncol."},{"key":"BFnrc2168_CR32","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1172\/JCI117872","volume":"95","author":"DK Ways","year":"1995","unstructured":"Ways, D. K. et al. MCF7 breast cancer cells transfected with protein kinase C-\u03b1 exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J. Clin. Invest. 95, 1906\u20131915 (1995).","journal-title":"J. Clin. Invest."},{"key":"BFnrc2168_CR33","doi-asserted-by":"publisher","first-page":"13169","DOI":"10.1074\/jbc.271.22.13169","volume":"271","author":"JY Lee","year":"1996","unstructured":"Lee, J. Y., Hannun, Y. A. & Obeid, L. M. Ceramide inactivates cellular protein kinase C alpha. J. Biol. Chem. 271, 13169\u201313174 (1996).","journal-title":"J. Biol. Chem."},{"key":"BFnrc2168_CR34","doi-asserted-by":"crossref","first-page":"19074","DOI":"10.1016\/S0021-9258(17)32276-7","volume":"269","author":"VL Goss","year":"1994","unstructured":"Goss, V. L., Hocevar, B. A. & Thompson, L. J. Identification of nuclear \u03b2 II protein kinase C as a mitotic lamin kinase. J. Biol. Chem. 269, 19074\u201319080 (1994).","journal-title":"J. Biol. Chem."},{"key":"BFnrc2168_CR35","doi-asserted-by":"publisher","first-page":"25436","DOI":"10.1074\/jbc.273.39.25436","volume":"273","author":"PP Ruvolo","year":"1998","unstructured":"Ruvolo, P. P., Deng, X. & Carr, B. K. A functional role for mitochondrial protein kinase C \u03b1 in Bcl2 phosphorylation and suppression of apoptosis. J. Biol. Chem. 273, 25436\u201325422 (1998).","journal-title":"J. Biol. Chem."},{"key":"BFnrc2168_CR36","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1042\/bj3520175","volume":"352","author":"MM Wert","year":"2000","unstructured":"Wert, M. M. & Palfrey, H. C. Divergence in the apoptotic signaling pathways used by nerve growth factor and basic fibroblast growth factor (bFGF) in PC12 cells: Rescue by bFGF involves protein kinase C \u03b4. Biochem. J. 352, 175\u2013182 (2000).","journal-title":"Biochem. J."},{"key":"BFnrc2168_CR37","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1038\/sj.onc.1203555","volume":"19","author":"T Cross","year":"2000","unstructured":"Cross, T, Griffiths, G. & Deacon, E. PKC is an apoptotic lamin kinase. Oncogene 19, 2331\u20132337 (2000).","journal-title":"Oncogene"},{"key":"BFnrc2168_CR38","first-page":"4612","volume":"61","author":"AS Mandil","year":"2001","unstructured":"Mandil, A. S., Ashkenazi, E. & Blass, M. Protein kinase C \u03b1 and protein kinase C \u03b4 play opposite roles in the proliferation and apoptosis of glioma cells. Cancer Res. 61, 4612\u20134619 (2001).","journal-title":"Cancer Res."},{"key":"BFnrc2168_CR39","first-page":"780","volume":"63","author":"A Clark","year":"2003","unstructured":"Clark, A. S, West, K. A. & Blumberg, P. M. Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKC\u03b4 promotes cellular survival and chemotherapeutic resistance. Cancer Res. 63, 780\u2013786 (2003).","journal-title":"Cancer Res."},{"key":"BFnrc2168_CR40","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.cellsig.2004.01.008","volume":"16","author":"C Partovian","year":"2004","unstructured":"Partovian, C. & Simons, M. Regulation of protein kinase B\/Akt activity and Ser473 phosphorylation by protein kinase Ca in endothelial cells. Cell. Signal. 16, 951\u2013957 (2004).","journal-title":"Cell. Signal."},{"key":"BFnrc2168_CR41","doi-asserted-by":"publisher","first-page":"47720","DOI":"10.1074\/jbc.M408797200","volume":"279","author":"Y Kawakami","year":"2004","unstructured":"Kawakami, Y. et al. Protein kinase C hII regulates Akt phosphorylation on Ser-473 in a cell type- and stimulus-specific fashion. J. Biol. Chem. 279, 47720\u201347725 (2004).","journal-title":"J. Biol. Chem."},{"key":"BFnrc2168_CR42","doi-asserted-by":"publisher","first-page":"9062","DOI":"10.1038\/sj.onc.1208093","volume":"23","author":"SE Aeder","year":"2004","unstructured":"Aeder, S. E. et al. PKC- mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways. Oncogene 23, 9062\u20139069 (2004).","journal-title":"Oncogene"},{"key":"BFnrc2168_CR43","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1128\/MCB.22.7.2099-2110.2002","volume":"22","author":"X Fang","year":"2002","unstructured":"Fang, X. et al. Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid througha protein kinase C-dependent intracellular pathway. Mol. Cell. Biol. 22, 2099\u20132110 (2002).","journal-title":"Mol. Cell. Biol."},{"key":"BFnrc2168_CR44","doi-asserted-by":"crossref","first-page":"16878","DOI":"10.1016\/S0021-9258(18)41866-2","volume":"267","author":"N Goode","year":"1992","unstructured":"Goode, N. et al. Differential regulation of glycogen synthase kinase-3 \u03b7 by protein kinase C isotypes. J. Biol. Chem. 267, 16878\u201316882 (1992).","journal-title":"J. Biol. Chem."},{"key":"BFnrc2168_CR45","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/378785a0","volume":"378","author":"DA Cross","year":"1995","unstructured":"Cross, D. A. et al. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785\u2013789 (1995).","journal-title":"Nature"},{"key":"BFnrc2168_CR46","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00280-001-0386-2","volume":"49","author":"BA Teicher","year":"2002","unstructured":"Teicher, B. A. et al. Antiangiogenic effects of a protein kinase C \u03b2-selective small molecule. Cancer Chemother. Pharmacol. 49, 69\u201377 (2002).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"BFnrc2168_CR47","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1073\/pnas.85.2.582","volume":"85","author":"RL Fine","year":"1988","unstructured":"Fine, R. L., Patel, J. & Chabner, B. A. Phorbol esters induce multidrug resistance in human breast cancer cells. Proc. Natl Acad. Sci. 85, 582\u2013586 (1988).","journal-title":"Proc. Natl Acad. Sci."},{"key":"BFnrc2168_CR48","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1023\/A:1013186430906","volume":"20","author":"CA O'Brian","year":"2001","unstructured":"O'Brian, C. A., Ward, N. E., Stewart, J. R. & Chu, F. Prospects for targeting protein kinase C isozymes in the therapy of drug-resistant cancer-an evolving story. Cancer Met. Rev. 20, 95\u2013100 (2001).","journal-title":"Cancer Met. Rev."},{"key":"BFnrc2168_CR49","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1074\/jbc.271.3.1708","volume":"271","author":"UA Germann","year":"1996","unstructured":"Germann, U. A. et al. Characterisation of phosphorylation \u2013 defective mutants of human P-glycoprotein expressed in mammalian cells. J. Biol. Chem. 271, 1708\u20131716 (1996).","journal-title":"J. Biol. Chem."},{"key":"BFnrc2168_CR50","doi-asserted-by":"publisher","first-page":"13668","DOI":"10.1074\/jbc.271.23.13668","volume":"271","author":"HR Goodfellow","year":"1996","unstructured":"Goodfellow, H. R. et al. Protein kinase C mediated phosphorylation does not regulate drug transport by the human multidrug resistance P-glycoprotein. J. Biol. Chem. 271, 13668\u201313674 (1996).","journal-title":"J. Biol. Chem."},{"key":"BFnrc2168_CR51","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/j.1349-7006.2001.tb01178.x","volume":"92","author":"JF Beck","year":"2001","unstructured":"Beck, J. F., Brugger, D. & Brischwein, K. Anticancer drug-mediated induction of multidrug resistance-associated genes and protein kinase C isozymes in the T-lymphoblastoid cell line CCRF-CEM and in blasts from patients with acute lymphoblastic leukemias. Jpn J. Cancer Res. 92, 896\u2013903 (2001).","journal-title":"Jpn J. Cancer Res."},{"key":"BFnrc2168_CR52","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1016\/j.ejca.2004.06.027","volume":"40","author":"PD Ainsworth","year":"2004","unstructured":"Ainsworth, P. D. et al. Protein kinase C \u03b1 expression in normal breast, ductal carcinoma in situ and invasive carcinoma. Euro. J. Cancer 40, 2269\u20132273 (2004).","journal-title":"Euro. J. Cancer"},{"key":"BFnrc2168_CR53","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2004.04.014","volume":"24","author":"A Varga","year":"2004","unstructured":"Varga, A. et al. Tumor grade-dependent alterations in the protein kinase C isoform pattern in urinary bladder carcinomas. Eur. Urol. 24, 462\u2013465 (2004).","journal-title":"Eur. Urol."},{"key":"BFnrc2168_CR54","first-page":"633","volume":"23","author":"W Weichart","year":"2003","unstructured":"Weichart, W. et al. Protein kinase C isoform expression in ovarian cancer correlates with indicators of poor prognosis. Int. J. Oncol. 23, 633\u2013639 (2003).","journal-title":"Int. J. Oncol."},{"key":"BFnrc2168_CR55","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1006\/gyno.2001.6164","volume":"81","author":"DB Fournier","year":"2001","unstructured":"Fournier, D. B. et al. Protein kinase C expression is inversely related to ER status in endometrial cancer: possible role in AP-1 mediated proliferation of ER negative endometrial cancer. Gynecol. Oncol. 81, 366\u2013372 (2001).","journal-title":"Gynecol. Oncol."},{"key":"BFnrc2168_CR56","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0002-9440(10)65260-1","volume":"54","author":"P Cornford","year":"1999","unstructured":"Cornford, P. et al. Protein kinase C isoenzyme patterns characteristically modulated in early prostate cancer. Am. J. Pathol. 54, 137\u2013144 (1999).","journal-title":"Am. J. Pathol."},{"key":"BFnrc2168_CR57","doi-asserted-by":"publisher","first-page":"4627","DOI":"10.1158\/0008-5472.CAN-05-4527","volume":"66","author":"L Ahang","year":"2006","unstructured":"Ahang, L. et al. Integrative genomic analysis of protein kinase C (PKC) family identifies PKC \u03b9 as a biomarker and potential oncogene in ovarian cancer. Cancer Res. 66, 4627\u20134635 (2006).","journal-title":"Cancer Res."},{"key":"BFnrc2168_CR58","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/j.1365-2559.2006.02461.x","volume":"49","author":"M Lahn","year":"2006","unstructured":"Lahn, M. et al. Immunohistochemical detection of protein kinase C-\u03b2 (PKC-\u03b2) in tumour specimens of patients with non-small cell lung cancer Histopathology 49, 426\u2013431 (2006).","journal-title":"Histopathology"},{"key":"BFnrc2168_CR59","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3816\/CLC.2004.n.032","volume":"6","author":"M Lahn","year":"2004","unstructured":"Lahn, M. et al. Expression level of protein kinase C \u03b1 in non small cell lung cancer. Clin. Lung Cancer 6, 184\u2013189 (2004).","journal-title":"Clin. Lung Cancer"},{"key":"BFnrc2168_CR60","first-page":"5353","volume":"52","author":"BE Andrejauskas","year":"1992","unstructured":"Andrejauskas, B. E. & Regenass, U. Differential inhibition of the epidermal growth factor-, platelet-derived growth factor, and protein kinase C-mediated signal transduction pathways by staurosporine derivative CGP41251. Cancer Res. 52, 5353\u20135358 (1992).","journal-title":"Cancer Res."},{"key":"BFnrc2168_CR61","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/ijc.2910570119","volume":"57","author":"I Utz","year":"1994","unstructured":"Utz, I. et al. The protein kinase inhibitor CGP41251, a staurosporine derivative with antitumour activity, reverses multidrug resistance. Int. J. Cancer 57, 104\u2013110 (1994).","journal-title":"Int. J. Cancer"},{"key":"BFnrc2168_CR62","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/bjc.1996.205","volume":"73","author":"J Budworth","year":"1996","unstructured":"Budworth, J. et al. Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to p-glycoprotein in multidrug-resistant MCF7\/Adr cells. Brit. J. Cancer 73, 1063\u20131068 (1996).","journal-title":"Brit. J. Cancer"},{"key":"BFnrc2168_CR63","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.2001.19.5.1485","volume":"19","author":"DJ Propper","year":"2001","unstructured":"Propper, D. J. et al. Phase I and pharmacokinetic study of PKC412 an inhibitor of protein kinase C. J. Clin. Oncol. 19, 1485\u20131492 (2001).","journal-title":"J. Clin. Oncol."},{"key":"BFnrc2168_CR64","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.4049\/jimmunol.153.4.1818","volume":"153","author":"L Shapira","year":"1994","unstructured":"Shapira, L. et al. Involvement of protein kinase C and protein tyrosine kinase in lipopolysaccharide-induced TNF\u03b1 and IL1\u03b2 production by human monocytes. J. Immunol. 153, 1818\u20131824 (1994).","journal-title":"J. Immunol."},{"key":"BFnrc2168_CR65","doi-asserted-by":"crossref","first-page":"841","DOI":"10.4049\/jimmunol.152.2.841","volume":"152","author":"JG Norris","year":"1994","unstructured":"Norris, J. G. et al. Signal transduction pathways mediating astrocyte IL-6 induction by IL-1\u03b2 and tumor necrosis factor-\u03b1. J. Immunol. 152, 841\u2013850 (1994).","journal-title":"J. Immunol."},{"key":"BFnrc2168_CR66","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1006\/cimm.1994.1267","volume":"158","author":"D Galron","year":"1994","unstructured":"Galron, D. et al. Inhibition of PMA-induced human Tcell proliferation by bryostatin is associated with enhanced degradation of cpnventional protein kinase C (cPKC): Ca++ signals restore mitogenic activity without abrogating enhanced cPKC degradation. Cell. Immunol. 158, 195\u2013207 (1994).","journal-title":"Cell. Immunol."},{"key":"BFnrc2168_CR67","doi-asserted-by":"crossref","first-page":"497","DOI":"10.4049\/jimmunol.156.2.497","volume":"156","author":"D Laxminarayana","year":"1996","unstructured":"Laxminarayana, D. & Kammer, G. M. Activation of type I protein kinase A during receptor mediated human T lymphocyte activation. J. Immunol. 156, 497\u2013506 (1996).","journal-title":"J. Immunol."},{"key":"BFnrc2168_CR68","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1084\/jem.193.4.497","volume":"193","author":"T Vang","year":"2001","unstructured":"Vang, T. et al. Activation of the COOH-terminal src kinase (Csk) by cAMP-dependent protein kinase inhibits signalling through the T cell receptor. J. Exp. Med. 193, 497\u2013507 (2001).","journal-title":"J. Exp. Med."},{"key":"BFnrc2168_CR69","first-page":"3980","volume":"59","author":"P Thavasu","year":"1999","unstructured":"Thavasu P . et al. The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-related kinase 2 expression in cancer patients. Cancer Res. 59, 3980\u20133984 (1999).","journal-title":"Cancer Res."},{"key":"BFnrc2168_CR70","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/00008390-200206000-00003","volume":"12","author":"E Selzer","year":"2002","unstructured":"Selzer, E. et al. Protein kinase C isoforms in normal and transformed cells of the melanocytic lineage. Melanoma Res. 12, 201\u2013209 (2002).","journal-title":"Melanoma Res."},{"key":"BFnrc2168_CR71","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/S0024-3205(02)02407-4","volume":"72","author":"N Yoshikawa","year":"2003","unstructured":"Yoshikawa, N. et al. Effect of PKC412, a selective inhibitor of protein kinase C, on lung metastasis in mice injected with B16 melanoma cells. Life Sci. 72, 1377\u20131387 (2003).","journal-title":"Life Sci."},{"key":"BFnrc2168_CR72","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/sj.bjc.6603331","volume":"95","author":"MJ Millward","year":"2006","unstructured":"Millward, M. J. et al. The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study. Br. J. Cancer 95, 829\u2013834 (2006).","journal-title":"Br. J. Cancer"},{"key":"BFnrc2168_CR73","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1200\/jco.2005.23.16_suppl.3016","volume":"23","author":"P Reichardt","year":"2005","unstructured":"Reichardt, P. et al. A phase I\/II trial of the oral PKC-inhibitor PKC412 (PKC) in combination with imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM. Proc. Amer. Soc. Clin. Oncol. 23, 3016 (2005).","journal-title":"Proc. Amer. Soc. Clin. Oncol."},{"key":"BFnrc2168_CR74","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.intimp.2005.02.012","volume":"5","author":"S Ming-Sing","year":"2005","unstructured":"Ming-Sing, S., Reitz, B. A. & Borie, D. C. Effects of the kinase inhibitor CGP41251(PKC412) on lymphocyte activation and TNF-\u03b1 production. Int. Immunopharmacol. 5, 1141\u20131149 (2005).","journal-title":"Int. Immunopharmacol."},{"key":"BFnrc2168_CR75","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00280-003-0713-x","volume":"53","author":"KA Keyes","year":"2004","unstructured":"Keyes, K. A. et al. LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother. Pharmacol. 53, 133\u2013140 (2004).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"BFnrc2168_CR76","doi-asserted-by":"crossref","first-page":"20037","DOI":"10.1200\/jco.2006.24.18_suppl.20037","volume":"24","author":"I Meinhold-Heerlein","year":"2006","unstructured":"Meinhold-Heerlein, I. et al. Effects of PKC \u03b2 inhibitor enzastaurin on parental and chemoresistant ovarian cancer cell lines. Proc. Amer. Soc. Clin. Oncol. 24, 20037 (2006).","journal-title":"Proc. Amer. Soc. Clin. Oncol."},{"key":"BFnrc2168_CR77","doi-asserted-by":"publisher","first-page":"7462","DOI":"10.1158\/0008-5472.CAN-05-0071","volume":"65","author":"JR Graff","year":"2005","unstructured":"Graff, J. R., McNulty, A. M. & Hanna, K. R. The protein kinase C \u03b2-selective inhibitor, Enzastaurin (LY317615. HCl) suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. 65, 7462\u20137469 (2005).","journal-title":"Cancer Res."},{"key":"BFnrc2168_CR78","doi-asserted-by":"publisher","first-page":"4092","DOI":"10.1200\/JCO.2005.05.3447","volume":"24","author":"MA Carducci","year":"2006","unstructured":"Carducci, M. A. et al. Phase I dose escalation and pharmacokinetic study of Enzastaurin, an oral protein kinase C \u03b2 inhibitor, in patients with advanced cancer. J. Clin. Oncol. 24, 4092\u20134099 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrc2168_CR79","doi-asserted-by":"publisher","first-page":"4054","DOI":"10.1200\/JCO.2006.07.4658","volume":"24","author":"A Adjei","year":"2006","unstructured":"Adjei, A. What is the right dose? The elusive optimal biologic dose in phase I clinical trials. J. Clin. Oncol. 24, 4054\u20134055 (2006).","journal-title":"J. Clin. Oncol."},{"key":"BFnrc2168_CR80","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.1158\/1078-0432.CCR-05-2231","volume":"12","author":"LJ Green","year":"2006","unstructured":"Green, L. J. et al. Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-\u03b2 inhibitor. Clin. Cancer. Res. 12, 3408\u20133415 (2006).","journal-title":"Clin. Cancer. Res."},{"key":"BFnrc2168_CR81","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1200\/jco.2005.23.16_suppl.1504","volume":"23","author":"HA Fine","year":"2005","unstructured":"Fine, H. A. et al. Results from phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas. Proc. Amer. Soc. Clin. Oncol. 23, 1504 (2005).","journal-title":"Proc. Amer. Soc. Clin. Oncol."},{"key":"BFnrc2168_CR82","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1200\/jco.2004.22.14_suppl.3129","volume":"22","author":"JM Rademaker-Lakhai","year":"2004","unstructured":"Rademaker-Lakhai, J. M. et al. Phase I and pharmacologic study of enzastaurin HCL, gemcitabine and cisplatin. Proc. Amer. Soc. Clin. Oncol. 22, 3129 (2004).","journal-title":"Proc. Amer. Soc. Clin. Oncol."},{"key":"BFnrc2168_CR83","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1200\/jco.2006.24.18_suppl.2048","volume":"24","author":"S Leong","year":"2006","unstructured":"Leong, S. et al. A phase I dose escalation and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced cancer. Proc. Amer. Soc. Clin. Oncol. 24, 2048 (2006).","journal-title":"Proc. Amer. Soc. Clin. Oncol."},{"key":"BFnrc2168_CR84","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1021\/np50077a004","volume":"54","author":"DE Schaufelberger","year":"1991","unstructured":"Schaufelberger, D. E. et al. The large scale isolation of bryostatin 1 from Bugula nerutina following current good manufacturing practices. J. Nat. Prod. 54, 1265\u20131270 (1991).","journal-title":"J. Nat. Prod."},{"key":"BFnrc2168_CR85","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/0006-291X(85)91898-4","volume":"132","author":"JB Smith","year":"1985","unstructured":"Smith, J. B., Smith, L. & Pettit, G. R. Bryostatins: potent, new mitogens that mimic phorbol ester tumour promoters. Biochem. Biophys. Res. Commun. 132, 939\u2013945 (1985).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnrc2168_CR86","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1016\/S0021-9258(17)42143-0","volume":"269","author":"Z Szallasi","year":"1994","unstructured":"Szallasi, Z., Smith, C. B., Pettit, G. R. & Blumberg, P. M. Differential regulation of protein kinase C isozymes by bryostatin 1 and phorbol 12-myrstate 13-acetate in NIH 3t3 fibroblasts. J. Biol. Chem. 269, 2118\u20132124 (1994).","journal-title":"J. Biol. Chem."},{"key":"BFnrc2168_CR87","first-page":"28","volume":"266","author":"BA Hocevar","year":"1991","unstructured":"Hocevar, B. A. & Fields, A. P. Selective translocation of \u03b2II protein kinase C to the nucleus of human promyelocytic (HL-60) leukemia cells. J. Cell. Biol. 266, 28\u201333 (1991).","journal-title":"J. Cell. Biol."},{"key":"BFnrc2168_CR88","first-page":"584","volume":"56","author":"C Stanwell","year":"1994","unstructured":"Stanwell, C. et al. The role of protein kinase C isoenzymes inhibition caused by bryostatin-1 in human A549 lung and MCF-7 breast carcinoma cells. Int. J. Cancer 56, 584\u2013592 (1994).","journal-title":"Int. J. Cancer"},{"key":"BFnrc2168_CR89","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1093\/carcin\/8.9.1343","volume":"9","author":"H Hennings","year":"1987","unstructured":"Hennings, H. et al. Bryostatin 1 activator of protein kinase C inhibits, tumor promotion by phorbol esters in sencar mouse skin. Carcinogenesis 9, 1343\u20131346 (1987).","journal-title":"Carcinogenesis"},{"key":"BFnrc2168_CR90","doi-asserted-by":"publisher","first-page":"20973","DOI":"10.1074\/jbc.271.35.20973","volume":"271","author":"H-W Lee","year":"1996","unstructured":"Lee, H-W . et al. Ubiquitination of protein kinase C \u03b1 and degradation by the proteosome. J. Biol. Chem. 271, 20973\u201320976 (1996).","journal-title":"J. Biol. Chem."},{"key":"BFnrc2168_CR91","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S0171-2985(87)80070-0","volume":"175","author":"H Mohr","year":"1987","unstructured":"Mohr, H., Pettit, G. R. & Plessing-Menze, A. Co-induction of lymphokine synthesis by the antineoplastic bryostatins. Immunobiology 175, 420\u2013430 (1987).","journal-title":"Immunobiology"},{"key":"BFnrc2168_CR92","doi-asserted-by":"crossref","first-page":"433","DOI":"10.4049\/jimmunol.140.2.433","volume":"140","author":"G Trenn","year":"1988","unstructured":"Trenn, G. et al. Immunomodulating properties of a novel series of protein kinase C activators. The biostatins. J. Immunol. 140, 433\u2013439 (1988).","journal-title":"J. Immunol."},{"key":"BFnrc2168_CR93","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/0006-2952(94)90484-7","volume":"47","author":"WD Jarvis","year":"1994","unstructured":"Jarvis, W. D. et al. Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-\u03b2-D-arabinofuranosylcytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells. Biochem. Pharmacol. 47, 839\u2013852 (1994).","journal-title":"Biochem. Pharmacol."},{"key":"BFnrc2168_CR94","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/0145-2126(95)00037-O","volume":"19","author":"RM Mohammed","year":"1995","unstructured":"Mohammed, R. M. et al. Bryostatin-1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma. Leuk. Res. 19, 667\u2013673 (1995).","journal-title":"Leuk. Res."},{"key":"BFnrc2168_CR95","first-page":"3119","volume":"52","author":"A Basu","year":"1992","unstructured":"Basu, A. & Lazo, J. S. Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum (II) by bryostatin-1. Cancer Res. 52, 3119\u20133124 (1992).","journal-title":"Cancer Res."},{"key":"BFnrc2168_CR96","doi-asserted-by":"publisher","first-page":"7059","DOI":"10.1158\/1078-0432.CCR-06-1419","volume":"12","author":"BF El-Rayes","year":"2006","unstructured":"El-Rayes, B. F. et al. Phase I study of bryostatin I and gemcitabine. Clin. Cancer Res. 12, 7059\u20137062 (2006).","journal-title":"Clin. Cancer Res."},{"key":"BFnrc2168_CR97","first-page":"1498","volume":"6","author":"JA Koutcher","year":"2000","unstructured":"Koutcher J. A. et al. The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow. Clin. Cancer Res. 6, 1498\u20131507 (2000).","journal-title":"Clin. Cancer Res."},{"key":"BFnrc2168_CR98","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1093\/jnci\/85.22.1812","volume":"85","author":"PA Philip","year":"1993","unstructured":"Philip, P. A. et al. Phase I study of bryostatin 1: assessment of interleukin 6 and tumour necrosis factor alpha induction in vivo. J. Natl Cancer Inst. 85, 1812\u20131818 (1993).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrc2168_CR99","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/bjc.1993.352","volume":"68","author":"J Prendiville","year":"1993","unstructured":"Prendiville, J. et al. A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br. J. Cancer 68, 418\u2013424 (1993).","journal-title":"Br. J. Cancer"},{"key":"BFnrc2168_CR100","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/bjc.1995.356","volume":"72","author":"GC Jayson","year":"1995","unstructured":"Jayson, G. C. et al. A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour infusion. Br. J. Cancer. 72, 461\u2013468 (1995).","journal-title":"Br. J. Cancer."},{"key":"BFnrc2168_CR101","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1038\/bjc.1998.680","volume":"78","author":"DJ Propper","year":"1998","unstructured":"Propper, D. J. et al. A phase II study of bryostatin 1 in metastatic malignant melanoma. Br. J. Cancer 78, 1337\u20131341 (1998).","journal-title":"Br. J. Cancer"},{"key":"BFnrc2168_CR102","first-page":"38","volume":"7","author":"JA Zonder","year":"2001","unstructured":"Zonder, J. A. et al. A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer. Clin. Cancer Res. 7, 38\u201342 (2001).","journal-title":"Clin. Cancer Res."},{"key":"BFnrc2168_CR103","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1200\/jco.2004.22.14_suppl.4223","volume":"22","author":"A Kaubisch","year":"2004","unstructured":"Kaubisch, A. et al. Phase II study of sequential paclitaxel (P) and bryostatin-1 (bryo) for patients with advanced pancreatic cancer. Proc. Amer. Soc. Clin. Oncol. 22, 4223 (2004).","journal-title":"Proc. Amer. Soc. Clin. Oncol."},{"key":"BFnrc2168_CR104","doi-asserted-by":"publisher","first-page":"4714","DOI":"10.1200\/jco.2005.23.16_suppl.4714","volume":"23","author":"GR Hudes","year":"2005","unstructured":"Hudes, G. R. et al. Phase II study of weekly paclitaxel (PAC) and brostatin-1 (bryo) in hormone refractory prostate cancer (HRPC). Proc. Amer. Soc. Clin. Oncol. 23, 4714 (2005).","journal-title":"Proc. Amer. Soc. Clin. Oncol."},{"key":"BFnrc2168_CR105","doi-asserted-by":"publisher","first-page":"4608","DOI":"10.1200\/jco.2004.22.14_suppl.4608","volume":"22","author":"AC Peterson","year":"2004","unstructured":"Peterson, A. C. et al. A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin in patients with renal cell carcinoma. Proc. Amer. Soc. Clin. Oncol. 22, 4608 (2004).","journal-title":"Proc. Amer. Soc. Clin. Oncol."},{"key":"BFnrc2168_CR106","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1200\/jco.2006.24.18_suppl.3067","volume":"24","author":"NB Haas","year":"2006","unstructured":"Haas, N. B. et al. Phase I study of intravenous CCI-779 in combination with bryostatin-1 in solid tumors. Proc. Amer. Soc. Clin. Oncol. 24, 3067 (2006).","journal-title":"Proc. Amer. Soc. Clin. Oncol."},{"key":"BFnrc2168_CR107","doi-asserted-by":"crossref","first-page":"16416","DOI":"10.1016\/S0021-9258(17)34023-1","volume":"269","author":"NM Dean","year":"1994","unstructured":"Dean, N. M., McKay, R., Condon, T. P. & Bennett, C. F. Inhibition of protein kinase C-\u03b1 expression in human A549 cells by antisense oligonucleotides inhibits induction of intracellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J. Biol. Chem. 269, 16416\u201316424 (1994).","journal-title":"J. Biol. Chem."},{"key":"BFnrc2168_CR108","first-page":"3499","volume":"56","author":"NM Dean","year":"1996","unstructured":"Dean, N. M. et al. Inhibition of growth of human tumour cell lines in nude mice by an antisense oligonucleotide inhibitor of protein kinase C \u03b1 expression. Cancer Res. 56, 3499\u20133507 (1996).","journal-title":"Cancer Res."},{"key":"BFnrc2168_CR109","first-page":"236","volume":"50","author":"T Yazaki","year":"1996","unstructured":"Yazaki T et al. Treatment of gioblastoma U-87 by systemic administration by an antisense protein kinase C\u03b1 phosphothioate oligodeoxynucleotide. Mol. Pharmacol. 50, 236\u2013242 (1996).","journal-title":"Mol. Pharmacol."},{"key":"BFnrc2168_CR110","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.1200\/JCO.1999.17.11.3586","volume":"17","author":"J Neumunaitis","year":"1999","unstructured":"Neumunaitis, J. et al. Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-\u03b1, in patients with advanced cancer. J. Clin. Oncol. 17, 3586\u20133595 (1999).","journal-title":"J. Clin. Oncol."},{"key":"BFnrc2168_CR111","first-page":"171","volume":"20","author":"WJ Gradishar","year":"2001","unstructured":"Gradishar, W. J. et al. A phase II trial with antisense oligonucleotide ISIS 3521\/Cgp 64128a in patients (Pts) with metastatic breast cancer (MBC): ECOG Trial 3197. Proc. Amer. Soc. Clin. Oncol. 20, abs. 171 (2001).","journal-title":"Proc. Amer. Soc. Clin. Oncol."},{"key":"BFnrc2168_CR112","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1215\/S1152851703000353","volume":"7","author":"SD Grossman","year":"2005","unstructured":"Grossman S. D. et al. Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-\u03b1 delivered as a 21 day continuous intraveneous infusion in patients with recurrent high-grade astrocytomas. Neuro-oncol. 7, 32\u201340 (2005).","journal-title":"Neuro-oncol."},{"key":"BFnrc2168_CR113","first-page":"1234","volume":"20","author":"AR Yuen","year":"2001","unstructured":"Yuen, A. R. et al. Phase I\/II trial of ISIS 3521, an antisense inhibitor of PKC-\u03b1, with carboplatin and paclitaxel in non-small cell lung cancer. Proc. Amer. Soc. Clin. Oncol. 20, abs 1234 (2001).","journal-title":"Proc. Amer. Soc. Clin. Oncol."},{"key":"BFnrc2168_CR114","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.lungcan.2005.12.012","volume":"52","author":"P Ritch","year":"2006","unstructured":"Ritch, P. et al. Phase II study of PKC\u03b1 antisense oligonucleotide aprinocarsen in combination with gemcitabine and cisplatin in patients with advanced non small cell lung cancer. Lung Cancer 52, 173\u2013180 (2006).","journal-title":"Lung Cancer"},{"key":"BFnrc2168_CR115","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2005.04.3299","volume":"24","author":"L Paz-Ares","year":"2006","unstructured":"Paz-Ares, L et al. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-\u03b1 antisense oligonucleotide, in patients with advanced stage non-small-cell lung cancer. J. Clin. Oncol. 24, 1428\u20131434 (2006).","journal-title":"J. Clin. Oncol."},{"issue":"623 abs","key":"BFnrc2168_CR116","first-page":"2504","volume":"22","author":"TJ Lynch","year":"2003","unstructured":"Lynch T. J. et al. Randomized phase III trial of chemotherapy and anti sense, oligonucleotide LY9000003 (ISIS 3521) in patients with advanced NSCLC: initial report. Proc. Am. Soc. Clin. Oncol. 22, 623 abs. 2504 (2003).","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"BFnrc2168_CR117","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1124\/jpet.106.108621","volume":"319","author":"EP Jane","year":"2006","unstructured":"Jane, E. P., Premkumar, D. R. & Pollack, I. F. Coadministration of sorafenib with rotterlin potently inhibits cell proliferation and migration in human malignant glioma cells. J. Pharmacol. Exp. Ther. 319, 1070\u20131080 (2006).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnrc2168_CR118","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00280-005-0125-1","volume":"57","author":"D Schaar","year":"2006","unstructured":"Schaar, D. et al. A phase I clinical trial of 12-O-tetradecanoylphorbol-13-acetate for patients with relapsed\/refractory malignancies. Cancer Chemother. Pharmacol. 57, 789\u2013795 (2006).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"BFnrc2168_CR119","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/0014-5793(93)80254-R","volume":"330","author":"K Mizuno","year":"1993","unstructured":"Mizuno, K., Saido, T. C., Ohno, S., Tamaoki, T. & Suzuki, K. Staurosporine-related compounds, K252a and UCN01, inhibit both cPKC and n PKC. FEBS lett. 330, 114\u2013116 (1993).","journal-title":"FEBS lett."},{"key":"BFnrc2168_CR120","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s002800050037","volume":"45","author":"CB Jones","year":"2000","unstructured":"Jones, C. B. et al. Enhancement of camptothecin-induced cytotoxicity with UCN01 in breast cancer cells: abrogation of S\/G2 arrest. Cancer Chemother. Pharmacol. 45, 252\u2013258 (2000).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"BFnrc2168_CR121","unstructured":"Bunch, R. T. & Eastman, A. Enhancement of cisplatin \u2013induced cytotoxicity by 7-hydroxystaurosporine (UCN01) a new G2-checkpoint inhibitor 1996. Clin. Cancer Res. 2 791\u2013797."},{"key":"BFnrc2168_CR122","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/(SICI)1097-0215(20000301)85:5<703::AID-IJC17>3.0.CO;2-7","volume":"85","author":"K Sugiyama","year":"2000","unstructured":"Sugiyama, K. et al. UCN01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and\/or G2 checkpoint abrogation. Int. J. Cancer 85, 703\u2013709 (2000).","journal-title":"Int. J. Cancer"},{"key":"BFnrc2168_CR123","first-page":"1054","volume":"58","author":"E Fuse","year":"1999","unstructured":"Fuse, E. et al. Altered pharmacokinetics of a novel anticancer drug, UCN01, caused by specific high affinity binding to \u03b11-acid glycoprotein in humans. Cancer Res. 58, 1054\u20131060 (1999).","journal-title":"Cancer Res."},{"key":"BFnrc2168_CR124","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1200\/JCO.2001.19.8.2319","volume":"19","author":"EA Sausville","year":"2001","unstructured":"Sausville, E. A. et al. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J. Clin. Oncol. 19, 2319\u20132333 (2001).","journal-title":"J. Clin. Oncol."},{"key":"BFnrc2168_CR125","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/1078-0432.664.11.2","volume":"11","author":"EC Dees","year":"2005","unstructured":"Dees, E. C. et al. A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors. Clin. Cancer Res. 11, 664\u2013667 (2005).","journal-title":"Clin. Cancer Res."},{"key":"BFnrc2168_CR126","doi-asserted-by":"crossref","first-page":"9194","DOI":"10.1016\/S0021-9258(18)98335-3","volume":"268","author":"G Martiny-Baron","year":"1993","unstructured":"Martiny-Baron, G. et al. Selective inhibition of protein kinase C isozymes by the indolocarbazole G06976. J. Biol. Chem. 268, 9194\u20139197 (1993).","journal-title":"J. Biol. Chem."},{"key":"BFnrc2168_CR127","first-page":"2462","volume":"45","author":"CA O'Brian","year":"1985","unstructured":"O'Brian, C. A., Liskamp, R. M., Solomon, D. H. & Weinstein, I. B. Inhibition of protein kinase C by tamoxifen. Cancer Res. 45, 2462\u20132465 (1985).","journal-title":"Cancer Res."},{"key":"BFnrc2168_CR128","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1042\/bj2940335","volume":"294","author":"SE Wilkinson","year":"1993","unstructured":"Wilkinson, S. E., Parker, P. J. & Nixon, J. S. Isoenzyme specificity of bisindolylmaleimides selective inhibitors of protein kinase C. Biochem. J. 294, 335\u2013337 (1993).","journal-title":"Biochem. J."},{"key":"BFnrc2168_CR129","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1200\/jco.2006.24.18_suppl.2047","volume":"24","author":"A Hanauske","year":"2006","unstructured":"Hanauske A et al. Pharmacokinetic interaction and safety of enzastaurin and premetrexed in patients with advanced or metastatic cancer. Proc. Amer. Soc. Clin. Onc. 24, 2047 (2006).","journal-title":"Proc. Amer. Soc. Clin. Onc."},{"key":"BFnrc2168_CR130","doi-asserted-by":"crossref","first-page":"13044","DOI":"10.1200\/jco.2006.24.18_suppl.13044","volume":"24","author":"RD Carvajal","year":"2006","unstructured":"Carvajal, R. D. et al. A phase I clinical trial of safingol followed by cisplatin: promising activity in refractory adrenocortical cancer with novel pharmacology. Proc. Amer. Soc. Clin. Oncol. 24, 13044 (2006).","journal-title":"Proc. Amer. Soc. Clin. Oncol."},{"key":"BFnrc2168_CR131","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1200\/jco.2005.23.16_suppl.3127","volume":"23","author":"H Hirte","year":"2005","unstructured":"Hirte, H. A phase II study of UCN 01 in combination with topotecan in patients with advanced recurrent ovarian cancer: a Princess Margaret Phase II Consortium trial. Proc. Amer. Soc. Clin. Oncol. 23, 3127 (2005).","journal-title":"Proc. Amer. Soc. Clin. Oncol."},{"key":"BFnrc2168_CR132","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1200\/JCO.2005.03.116","volume":"25","author":"J Kortmansky","year":"2005","unstructured":"Kortmansky, J. et al. Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystauroporine in combination with fluorouracil in patients with advanced solid tumors. J. Clin. Oncol. 25, 1875\u20131884 (2005).","journal-title":"J. Clin. Oncol."}],"updated-by":[{"DOI":"10.1038\/nrc2350","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000}}],"container-title":["Nature Reviews Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrc2168.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrc2168","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrc2168.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:22:42Z","timestamp":1684466562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrc2168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7]]},"references-count":132,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,7]]}},"alternative-id":["BFnrc2168"],"URL":"https:\/\/doi.org\/10.1038\/nrc2168","relation":{},"ISSN":["1474-175X","1474-1768"],"issn-type":[{"value":"1474-175X","type":"print"},{"value":"1474-1768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7]]}}}